This guide is general education for pet owners. If your pet has urgent symptoms, possible poisoning, injury, breathing trouble, collapse, severe pain, or sudden decline, contact a licensed veterinarian or local emergency service.
Editorial standard
How this guide was prepared
Edited for decisionsNewsPet guides are structured around practical owner choices, tradeoffs, and safety boundaries.
Source policySources are listed when a guide relies on outside references.
Veterinary boundaryThis article does not diagnose or prescribe; urgent symptoms need veterinary care.
CorrectionsReaders can flag unclear, outdated, or inaccurate information through our contact page.
Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitor
Approved Uses: Reduction of glomerular proteinuria in feline and canine Chronic Kidney Disease (CKD), systemic hypertension, and adjunctive therapy in canine Congestive Heart Failure (CHF).
Mechanism of Action (Pharmacodynamics)
Inhibits the conversion of Angiotensin I to Angiotensin II, abolishing vasoconstriction and decreasing aldosterone production. In the kidneys, it preferentially dilates efferent arterioles, reducing intraglomerular hypertension and protein loss.
Figure 1: Pharmaceutical exhibit of Benazepril and Enalapril ACE inhibitor tablets with clinical laboratory requisition orders for mandatory 14-day serial serum creatinine and potassium monitoring.
Severe hypotension: extreme weakness, collapse, cold extremities; acute severe azotemia or hyperkalemia.
Figure 2: Feline clinical Doppler sphygmomanometry. Non-invasive radial arterial blood pressure evaluation to titrate ACE inhibitor therapy against systemic hypertension and renal proteinuria.
Clinical Contraindications & Interactions
Do Not Use In: Hypovolemia, severe dehydration, acute kidney injury (AKI), or breeding/pregnant animals. Benazepril is preferred in cats over enalapril due to dual hepatic-renal clearance pathways.
Strict Rule S1 Veterinary Prescription Directive
VETERINARY DIRECTIVE: A modest increase in creatinine (up to 30%) is an expected hemodynamic response to efferent dilation. However, serum electrolytes (especially potassium) and renal parameters must be evaluated 1 to 2 weeks following initiation. Never administer concurrently with potassium-sparing diuretics without close monitoring. Never administer human pharmaceutical products or adjust dosages without direct examination and bloodwork by a licensed Doctor of Veterinary Medicine (DVM).